Literature DB >> 35027481

Targeting Protein Arginine Methyltransferase 5 Suppresses Radiation-induced Neuroendocrine Differentiation and Sensitizes Prostate Cancer Cells to Radiation.

Elena Beketova1,2, Sheng Liu3,4, Jake L Owens1, Qi Shen1, Jogendra Singh Pawar1, Andrew M Asberry1,2, Jie Yang1, Xuehong Deng1, Bennett D Elzey5,6, Timothy L Ratliff5,6, Liang Cheng7, Richard Choo8, Deborah E Citrin9, Thomas J Polascik10, Bangchen Wang11, Jiaoti Huang11, Chenglong Li12, Jun Wan3,4,13,14, Chang-Deng Hu1,6.   

Abstract

Prostate cancer remains the second leading cause of cancer death among American men. Radiotherapy is a potentially curative treatment for localized prostate cancer, and failure to control localized disease contributes to the majority of prostate cancer deaths. Neuroendocrine differentiation (NED) in prostate cancer, a process by which prostate adenocarcinoma cells transdifferentiate into neuroendocrine-like (NE-like) cells, is an emerging mechanism of resistance to cancer therapies and contributes to disease progression. NED also occurs in response to treatment to promote the development of treatment-induced neuroendocrine prostate cancer (NEPC), a highly aggressive and terminal stage disease. We previously demonstrated that by mimicking clinical radiotherapy protocol, fractionated ionizing radiation (FIR) induces prostate cancer cells to undergo NED in vitro and in vivo. Here, we performed transcriptomic analysis and confirmed that FIR-induced NE-like cells share some features of clinical NEPC, suggesting that FIR-induced NED represents a clinically relevant model. Furthermore, we demonstrated that protein arginine methyltransferase 5 (PRMT5), a master epigenetic regulator of the DNA damage response and a putative oncogene in prostate cancer, along with its cofactors pICln and MEP50, mediate FIR-induced NED. Knockdown of PRMT5, pICln, or MEP50 during FIR-induced NED and sensitized prostate cancer cells to radiation. Significantly, PRMT5 knockdown in prostate cancer xenograft tumors in mice during FIR prevented NED, enhanced tumor killing, significantly reduced and delayed tumor recurrence, and prolonged overall survival. Collectively, our results demonstrate that PRMT5 promotes FIR-induced NED and suggests that targeting PRMT5 may be a novel and effective radiosensitization approach for prostate cancer radiotherapy. ©2022 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35027481      PMCID: PMC8898292          DOI: 10.1158/1535-7163.MCT-21-0103

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.009


  50 in total

1.  Bioinformatics analyses of publicly available NEPCa datasets.

Authors:  Siyuan Cheng; Xiuping Yu
Journal:  Am J Clin Exp Urol       Date:  2019-10-15

Review 2.  The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond.

Authors:  Nicole Stopa; Jocelyn E Krebs; David Shechter
Journal:  Cell Mol Life Sci       Date:  2015-02-07       Impact factor: 9.261

3.  Biology and evolution of poorly differentiated neuroendocrine tumors.

Authors:  David S Rickman; Himisha Beltran; Francesca Demichelis; Mark A Rubin
Journal:  Nat Med       Date:  2017-06-06       Impact factor: 53.440

4.  Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml.

Authors:  Yu-Hsuan Shao; Peter C Albertsen; Calpurnyia B Roberts; Yong Lin; Amit R Mehta; Mark N Stein; Robert S DiPaola; Grace L Lu-Yao
Journal:  Arch Intern Med       Date:  2010-07-26

5.  Ca2+ homeostasis and apoptotic resistance of neuroendocrine-differentiated prostate cancer cells.

Authors:  K Vanoverberghe; F Vanden Abeele; P Mariot; G Lepage; M Roudbaraki; J L Bonnal; B Mauroy; Y Shuba; R Skryma; N Prevarskaya
Journal:  Cell Death Differ       Date:  2004-03       Impact factor: 15.828

6.  Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma.

Authors:  Thomas Fixemer; Klaus Remberger; Helmut Bonkhoff
Journal:  Prostate       Date:  2002-10-01       Impact factor: 4.104

Review 7.  Treatment strategies for high-risk locally advanced prostate cancer.

Authors:  Seth A Rosenthal; Howard M Sandler
Journal:  Nat Rev Urol       Date:  2010-01       Impact factor: 14.432

8.  The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation.

Authors:  S S Tarighat; R Santhanam; D Frankhouser; H S Radomska; H Lai; M Anghelina; H Wang; X Huang; L Alinari; A Walker; M A Caligiuri; C M Croce; L Li; R Garzon; C Li; R A Baiocchi; G Marcucci
Journal:  Leukemia       Date:  2015-11-05       Impact factor: 11.528

Review 9.  Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure.

Authors:  Chang-Deng Hu; Richard Choo; Jiaoti Huang
Journal:  Front Oncol       Date:  2015-04-14       Impact factor: 6.244

10.  Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers.

Authors:  Yan Zhang; Dayong Zheng; Ting Zhou; Haiping Song; Mohit Hulsurkar; Ning Su; Ying Liu; Zheng Wang; Long Shao; Michael Ittmann; Martin Gleave; Huanxing Han; Feng Xu; Wangjun Liao; Hongbo Wang; Wenliang Li
Journal:  Nat Commun       Date:  2018-10-04       Impact factor: 14.919

View more
  3 in total

Review 1.  Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance.

Authors:  Rongbin Ge; Zongwei Wang; Liang Cheng
Journal:  NPJ Precis Oncol       Date:  2022-05-04

Review 2.  The Roles of Tumor-Associated Macrophages in Prostate Cancer.

Authors:  Chenglin Han; Yuxuan Deng; Wenchao Xu; Zhuo Liu; Tao Wang; Shaogang Wang; Jihong Liu; Xiaming Liu
Journal:  J Oncol       Date:  2022-09-07       Impact factor: 4.501

3.  Expression, Localization and Prognosis Association of MEP50 in Breast Cancer.

Authors:  Samyuktha Suresh; Mathilde Vinet; Rayan Dakroub; Laetitia Lesage; Mengliang Ye; Hussein Fayyad-Kazan; André Nicolas; Didier Meseure; Thierry Dubois
Journal:  Cancers (Basel)       Date:  2022-09-29       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.